FDA approves Hospira's generic Hycamtin

LAKE FOREST, Ill. — The Food and Drug Administration has approved a generic cancer drug from Hospira.

The drug maker announced the approval of topotecan injection for treating small-cell lung cancer sensitive disease after first-line chemotherapy has failed.

The drug is a generic version of GlaxoSmithKline’s Hycamtin, which had sales of more than $140 million in 2010, according to Hospira.

Login or Register to post a comment.